"We are delighted to welcome Erik as a permanent part of our team," says Alzinova CEO Tord Labuda. "With the recent positive results from our Phase 1b study, it is crucial to have the right skills in place to drive our exciting journey forward. Erik's experience and commitment will be central to Alzinova's continued development of a potential vaccine against Alzheimer's disease."

"It is with joy and commitment that I now take up the position as permanent CFO of Alzinova. I look forward to being part of a dedicated team with full focus on contributing an important piece of the puzzle in the treatment of Alzheimer's disease," says Erik Kullgren.

For more information, please contact:
Tord Labuda, CEO
E-mail: tord.labuda@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com